Patents by Inventor Mari Dezawa
Mari Dezawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220387507Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.Type: ApplicationFiled: October 30, 2020Publication date: December 8, 2022Applicants: Life Science Institute, Inc., National University Corporation Tokai National Higher Education and Research System, THE JIKEI UNIVERSITY, TOHOKU UNIVERSITYInventors: Tokunori YAMAMOTO, Shinobu SHIMIZU, Akira FURUTA, Mari DEZAWA, Yasumasa KURODA
-
Patent number: 11512284Abstract: There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention.Type: GrantFiled: January 7, 2019Date of Patent: November 29, 2022Assignee: SanBio, Inc.Inventors: Mari Dezawa, Hajime Sawada, Hiroshi Kanno, Masahiko Takano
-
Publication number: 20220370510Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.Type: ApplicationFiled: July 29, 2022Publication date: November 24, 2022Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
-
Publication number: 20220323509Abstract: Provided is a cell product for treating myocarditis, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a SSEA-3-positive pluripotent stem cell derived from a cultured mesenchymal cell.Type: ApplicationFiled: September 4, 2020Publication date: October 13, 2022Applicants: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.Inventors: Mari DEZAWA, Yoshikatsu SAIKI, Hiroki TAKAYA
-
Publication number: 20220313741Abstract: A method for treating or repairing osteochondral damage in a subject in need thereof, including administering to the subject a cell preparation comprising pluripotent stem cells positive for SSEA-3 isolated from a body mesenchymal tissue or cultured mesenchymal cells. The pluripotent stem cells have all of the following properties: (i) CD105-positivity; (ii) low or absent telomerase activity; (iii) having ability to differentiate into any of three germ layers; (iv) absence of demonstration of neoplastic proliferation; and (v) self-renewal ability. The pluripotent stem cells are administered at 1×103 cells to 2×107 cells as individual.Type: ApplicationFiled: June 21, 2022Publication date: October 6, 2022Applicants: Hiroshima University, TOHOKU UNIVERSITYInventors: Naosuke KAMEI, Mari DEZAWA, Mitsuo OCHI
-
Patent number: 11419899Abstract: A cell product for prevention and/or treatment of vascular disorders such as aortic aneurysm, comprising a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell (Muse cell).Type: GrantFiled: July 28, 2017Date of Patent: August 23, 2022Assignees: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE INC.Inventors: Yoshikatsu Saiki, Mari Dezawa, Katsuhiro Hosoyama
-
Publication number: 20220169979Abstract: This disclosure describes efficient methods for separating desired populations of cells, including Multilineage-Differentiating Stress-Enduring (MUSE) cells. Also described are the methods for isolating and enriching MUSE cells through a sorting, expanding, and re-sorting procedure. The enriched cells or cell populations can be used for treating cancer, repairing various tissues, and treating various degenerative or inherited diseases.Type: ApplicationFiled: April 9, 2020Publication date: June 2, 2022Applicants: Rutgers, The State University of New Jersey, Life Science Institute, Inc.Inventors: Wise Young, Dongming Sun, Iman Tadmori, Zikuan Leng, Mari Dezawa
-
Patent number: 11261426Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.Type: GrantFiled: June 22, 2016Date of Patent: March 1, 2022Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Youichi Nabeshima
-
Publication number: 20220000936Abstract: A cell product may be used for treating a peripheral blood flow disorder, and the cell product may include an SSEA-3-positive pluripotent stem cells (Muse cells) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. The peripheral blood flow disorder is preferably a peripheral arterial disease, more preferably chronic arterial obstruction in a limb.Type: ApplicationFiled: November 29, 2019Publication date: January 6, 2022Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, LIFE SCIENCE INSTITUTE, INC.Inventors: Satoaki MATOBA, Mari DEZAWA
-
Publication number: 20210213068Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.Type: ApplicationFiled: March 31, 2021Publication date: July 15, 2021Applicants: LIFE SCIENCE INSTITUTE, INC., TOHOKU UNIVERSITYInventors: Masanori Yoshida, Mari Dezawa, Teiji Tominga
-
Patent number: 11000552Abstract: The purpose of the present invention is to provide a novel medicinal use in regeneration medicine, said medicinal use comprising using pluripotent stem cells (Muse cells). Provided is a cell preparation for treating skin ulcer, said cell preparation comprising SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue of a living organism or cultured mesenchymal cells. The cell preparation according to the present invention is based on such mechanism of skin tissue regeneration that, when the Muse cells are administered to a skin ulcer site of a subject suffering from the aforesaid disease, the Muse cells differentiate into skin-constituting cells.Type: GrantFiled: February 28, 2019Date of Patent: May 11, 2021Assignees: The University of Tokyo, Tohoku UniversityInventors: Kotaro Yoshimura, Kahori Kinoshita, Mari Dezawa
-
Patent number: 10993966Abstract: An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma.Type: GrantFiled: January 23, 2017Date of Patent: May 4, 2021Assignees: LIFE SCIENCE INSTITUTE, INC., TOHOKU UNIVERSITYInventors: Masanori Yoshida, Mari Dezawa, Teiji Tominaga
-
Publication number: 20200254026Abstract: An agent for promoting migration of pluripotent stem cells containing an extract from inflamed tissues inoculated with vaccinia virus. An extract from inflamed tissues inoculated with vaccinia virus promotes migration of Muse cells. Thus, the agent for promoting migration of pluripotent stem cells for various diseases to which migration of pluripotent stem cells may have an advantageous effect.Type: ApplicationFiled: April 28, 2020Publication date: August 13, 2020Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Mari DEZAWA, Mieko OHTSU
-
Publication number: 20200237828Abstract: Multilineage-differentiating stress enduring (Muse) cells are stage-specific embryonic antigen-3 (SSEA-3) positive cells that exist in mesenchymal stem cell (MSC) populations. Muse cells have the pluripotency to differentiate into all germ layers as embryonic stem cells. The purpose of the present study is to investigate the efficacy of Muse cell transplantation for repairing osteochondral defects. Muse cells were isolated from human bone marrow MSCs. As osteochondral defects, the patellar grooves of immunodeficient rats were injured. Next, cells were injected into the mice so that the animals were divided into the following 3 groups: a control group to which PBS was injected; a non-Muse group to which 5×104 SSEA-3 negative non-Muse cells were injected; and a Muse group to which 5×104 SSEA-3 positive Muse cells were injected.Type: ApplicationFiled: October 17, 2018Publication date: July 30, 2020Applicants: HIROSHIMA UNIVERSITY, TOHOKU UNIVERSITYInventors: Naosuke KAMEI, Mari DEZAWA, Mitsuo OCHI
-
Publication number: 20200197446Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.Type: ApplicationFiled: June 20, 2018Publication date: June 25, 2020Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
-
Patent number: 10639335Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.Type: GrantFiled: June 25, 2019Date of Patent: May 5, 2020Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITYInventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
-
Patent number: 10641762Abstract: Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.Type: GrantFiled: January 16, 2017Date of Patent: May 5, 2020Assignees: UNIVERSITY OF TOYAMA, LIFE SCIENCE INSTITUTE, INC.Inventors: Mari Dezawa, Satoshi Kuroda
-
Publication number: 20190307806Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.Type: ApplicationFiled: June 25, 2019Publication date: October 10, 2019Applicants: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITYInventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa
-
Publication number: 20190290702Abstract: The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition both for ameliorating and treating perinatal brain damage including learning disability and motor disability, each of the cell preparation and the pharmaceutical composition containing SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue collected from a living body or cultured mesenchymal cells. The cell preparation according to the present invention relies on a mechanism that Muse cells are administered to a subject having the above-mentioned damage to cause the engraftment of the Muse cells in a damaged brain tissue, thereby ameliorating and treating the damage.Type: ApplicationFiled: May 16, 2017Publication date: September 26, 2019Applicants: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.Inventors: Yoshiaki Sato, Toshihiko Suzuki, Shinobu Shimizu, Masaaki Mizuno, Masahiro Hayakawa, Mari Dezawa
-
Patent number: 10376544Abstract: An object of the present invention is to provide a novel medical application for use in regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating myocardial infarction, and particularly serious massive myocardial infarction and heart failure associated therewith, that contains pluripotent stem cells positive for SSEA-3 isolated from biological mesenchymal tissue or cultured mesenchymal cells. The cell preparation of the present invention is based on a cardiac tissue regeneration mechanism by which Muse cells are made to selectively accumulate in damaged myocardial tissue and differentiate into cardiac muscle in that tissue as a result of intravenous administration of Muse cells to a subject presenting with the aforementioned disorders.Type: GrantFiled: November 3, 2017Date of Patent: August 13, 2019Assignees: CLIO, INC., GIFU UNIVERSITY, TOHOKU UNIVERSITYInventors: Masanori Yoshida, Shinya Minatoguchi, Mari Dezawa